Sorrento Therapeutics, Inc.
SRNE · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $15 | $16 | $16 | $17 |
| % Growth | -7.5% | 4.2% | -10.4% | – |
| Cost of Goods Sold | $8 | $5 | $14 | $8 |
| Gross Profit | $7 | $11 | $2 | $9 |
| % Margin | 43.7% | 68.1% | 12% | 52.5% |
| R&D Expenses | $33 | $44 | $41 | $68 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $49 | $55 | $39 | $50 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | -$0 | $1 | $1 |
| Operating Expenses | $84 | $100 | $82 | $119 |
| Operating Income | -$77 | -$106 | -$170 | -$110 |
| % Margin | -514% | -654.4% | -1,087.8% | -633% |
| Other Income/Exp. Net | -$31 | -$36 | -$41 | $18 |
| Pre-Tax Income | -$108 | -$143 | -$210 | -$92 |
| Tax Expense | $1 | $11 | -$2 | -$1 |
| Net Income | -$95 | -$140 | -$224 | -$91 |
| % Margin | -633.7% | -859.1% | -1,434.5% | -521.2% |
| EPS | -0.17 | -0.26 | -0.51 | -0.2 |
| % Growth | 34.6% | 49% | -155% | – |
| EPS Diluted | -0.17 | -0.26 | -0.51 | -0.2 |
| Weighted Avg Shares Out | 551 | 543 | 435 | 452 |
| Weighted Avg Shares Out Dil | 551 | 543 | 435 | 452 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $1 | $2 | $1 |
| Depreciation & Amortization | $6 | $5 | $3 | $4 |
| EBITDA | -$99 | -$137 | -$205 | -$87 |
| % Margin | -662.1% | -841.4% | -1,314.1% | -498.5% |